Tubular carcinoma of the breast is a distinct, relatively rare low-grade neoplasm, accounting for approximately 1 to 2% of invasive breast cancers. It is composed of well-differentiated tubular structures with open lumina, typically one layer thick surrounded by abundant stroma. Because of its nonaggressive, histologic appearance, its low propensity to recur locally, spread to axillary lymph nodes, and metastasize distantly, pure tubular carcinoma carries a favorable prognosis. Its diagnosis is established based on histopathological examination of the surgical specimen.
Genetic alterations in tubular carcinoma are uncommon. They mainly include chromosomes 16q (loss) (78 to 86%) and 1q (gain) (50 to 62%), and they often occur concomitantly.
Other alterations include loss of 8p, 3p (FHIT gene locus) and 16p gain and 11q (ATM gene locus). Gene expression profiling studies have proven that tubular carcinoma belongs to the “luminal A” molecular class of breast cancer.
Studies analyzing morphologic features of tumors arising in carriers of BRCA1 or BRCA2 mutations and non-BRCA1/2 families have not reported a frequent association of tubular carcinoma in these subsets of patients.
Pure tubular carcinoma accounts for approximately 1 to 2% of invasive breast cancers. Its frequency is higher in populations where there is screening mammography.
Tubular carcinomas predominate in women in their sixth or seventh decade who underwent breast cancer screening (mean age at onset is between 54 and 60 years).
As for other forms of breast cancers, tubular carcinoma is very rare in male patients.
Its preferential site of involvement is in the upper outer quadrant of the breast. Multifocality presents in 20% of the cases.
Reports show a higher frequency in whites compared with blacks..
The characteristic feature of tubular carcinoma is the predominance of open tubules composed of a single layer of epithelial cells enclosing a clear lumen. These should comprise over 90% of the tumor. The tubules are generally an admixture of oval or rounded and angulated shapes and arranged haphazardly. The cells are small to moderate in size, regular with little nuclear pleomorphism, inconspicuous nucleoli, and scanty mitotic figures. Myoepithelial cells are absent around the tubules, but some may have an incomplete surrounding layer of the basement membrane. A secondary but essential feature is the cellular desmoplastic stroma, commonly accompanying the tubular structures. Tubular carcinoma occurs in association with flat epithelial atypia, low-grade ductal carcinoma in situ, and less commonly tubular neoplasia . There is a lack of consensus concerning the proportion of tubular structures necessary for a diagnosis of tubular carcinoma, with the requirement set at between 75% and 100%, but 90% purity offers a practical solution and is recommended . Tumors exhibiting between 50% and 90% tubules admixed with another morphology should be regarded as being of mixed type.
Tubular carcinoma is nearly always positive for estrogen and progesterone receptors has a low growth fraction and is typically negative for HER2, EGFR, P-cadherin, p53, and high molecular weight keratins.
There is no specific clinical feature that distinguishes tubular carcinoma from the more common invasive carcinomas of no particular type or other types. Initially, tubular breast carcinoma may not cause any symptoms. Over time, a lump may grow large enough to be detected during breast self-examination or examination by a doctor. Tubular carcinomas are usually small, measuring 1 cm or less in diameter and are firm or hard in consistency.
The mammographic abnormality reported in the majority of patients with tubular carcinomas is a mass lesion with central density, occasionally with microcalcifications. The mass may appear round, oval, or lobulated, with irregular or spiculated margins. Tubular carcinomas cannot be distinguished reliably from invasive duct carcinomas and sometimes from radial scars on imaging studies, as these lesions show similar architectural patterns. Because of the high incidence of other types of coexisting carcinoma in the ipsilateral or developing carcinoma in the contralateral breast, bilateral mammography at the time of diagnosis is important.
Ultrasonography is particularly helpful in detecting some of the mammographically occult tumors. On ultrasonography, tubular carcinoma appears as an irregularly contoured mass with posterior acoustic shadowing.
Magnetic resonance imaging:
On magnetic resonance imaging, some authors observed enhancement patterns that could help to differentiate tubular carcinoma from other histological subtypes.
Because of its favorable prognosis, some studies have proposed that a diagnosis of tubular carcinoma might warrant less aggressive surgical or adjuvant treatment. Specifically, some have challenged the need for radiation therapy for patients who have undergone breast-conserving surgery, while others have questioned the prognostic value of axillary staging and the necessity of adjuvant systemic therapy. Until there is the better establishment of the value of nodal status, lymph node evaluation should still be considered in patients with tumors of less than 1 cm, because a small primary tumor size does not preclude nodal involvement. Due to the low invasiveness of tubular carcinoma, breast preservation therapy, with or without radiotherapy, is probably the best approach, in particular when no nodal metastasis presents. According to some authors, adjuvant radiation therapy reduces the incidence of local failure following conservative surgery for tubular carcinoma. However, elderly tubular patients treated by conservative surgery appear to have a very low risk of local recurrence without radiation therapy.
Because almost all tubular carcinomas express hormone receptors, some form of adjuvant hormonal treatment applies to most patients. The decision regarding systemic adjuvant chemotherapy should be individualized and based on tumor size, grade, and lymph node status. Chemotherapy is typically not recommended to patients with tubular carcinoma given the excellent prognosis, low risk for recurrence, and adverse side effects that significantly outweigh the small benefit chemotherapy may have. The 2015 National Comprehensive Cancer Network guidelines do not recommend adjuvant endocrine therapy for patients with tumors less than 10 mm and favorable histology such as tubular carcinoma with or without micrometastasis or isolated tumor cells in lymph nodes. If the tumor is estrogen receptor (ER) positive, one may consider endocrine therapy for risk reduction and to diminish the small risk of disease recurrence. If the tumor is between 10 and 29 mm, one should consider giving adjuvant endocrine therapy. In patients with tumors more than or equal to 30 mm, adjuvant endocrine therapy should be the treatment. In patients with macrometastasis in one or more nodes, one should consider giving adjuvant chemotherapy along with endocrine therapy.
Staging of tubular carcinoma of the breast is determined clinically by physical examination and imaging studies before treatment and is determined pathologically by pathologic examination of the primary tumor and regional lymph nodes after definitive surgical treatment. The most widely used clinical staging system for medullary breast carcinoma is the one adopted by both the International Union for Cancer Control (UICC) and the American Joint Commission on Cancer (AJCC). Its basis is in the TNM system (T, tumor; N, nodes; M, metastases). T, N, and M are combined to create five stages (stage 0, I, II, III and IV) that summarize information about the extent of the regional disease (tumor size, skin, or chest-wall invasion and nodal involvement) and metastasis to distant sites.
Patients with pure tubular carcinoma have an excellent prognosis compared with invasive ductal carcinoma. Ten-year disease-free survival and overall survival rates after mastectomy or partial resection have been reported to be 93.1 to 99.1% and 99 to 100% respectively. Axillary lymph node metastases occur infrequently and rarely involve more than one axillary lymph node. Even when patients have axillary metastases from tubular carcinoma, the prognosis is very good.
Patients must be instructed to self-examine their breasts regularly and consult their doctors if any abnormality detected.
Tubular carcinoma is a special type of invasive carcinoma with a distinctive morphologic appearance and excellent prognosis. Management of tubular breast carcinoma needs an interdisciplinary approach involving a team that consists of a surgical oncologist, an oncologist, a pathologist, a radiologist, and a specialty trained nurse. Careful planning and discussion with other professionals involved in the management of patients with tubular carcinoma will improve patient outcomes. Despite its excellent prognosis, careful long-term follow-up is essential for tubular carcinoma because local recurrences can occur after many years. Moreover, the mammographic monitoring of the contralateral breast is critical. The primary care provider and nurse practitioner must refer patients with suspected breast masses to an oncologist for further workup. Pharmacists evaluate prescribed medications, check for drug-drug interactions, and educate patients and their families. Oncology nurses are involved in treatment and education. They also inform the team about changes in the status of the patients.
Tubular carcinoma requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level V]
|||Goldstein NS,Kestin LL,Vicini FA, Refined morphologic criteria for tubular carcinoma to retain its favorable outcome status in contemporary breast carcinoma patients. American journal of clinical pathology. 2004 Nov; [PubMed PMID: 15491969]|
|||McDivitt RW,Boyce W,Gersell D, Tubular carcinoma of the breast. Clinical and pathological observations concerning 135 cases. The American journal of surgical pathology. 1982 Jul; [PubMed PMID: 6289683]|
|||Rakha EA,Lee AH,Evans AJ,Menon S,Assad NY,Hodi Z,Macmillan D,Blamey RW,Ellis IO, Tubular carcinoma of the breast: further evidence to support its excellent prognosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Jan 1; [PubMed PMID: 19917872]|
|||Sullivan T,Raad RA,Goldberg S,Assaad SI,Gadd M,Smith BL,Powell SN,Taghian AG, Tubular carcinoma of the breast: a retrospective analysis and review of the literature. Breast cancer research and treatment. 2005 Oct; [PubMed PMID: 16142444]|
|||Anderson WF,Chu KC,Chang S,Sherman ME, Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer epidemiology, biomarkers [PubMed PMID: 15247123]|
|||Diab SG,Clark GM,Osborne CK,Libby A,Allred DC,Elledge RM, Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 May; [PubMed PMID: 10334529]|
|||Fedko MG,Scow JS,Shah SS,Reynolds C,Degnim AC,Jakub JW,Boughey JC, Pure tubular carcinoma and axillary nodal metastases. Annals of surgical oncology. 2010 Oct; [PubMed PMID: 20853056]|
|||Fernández-Aguilar S,Simon P,Buxant F,Simonart T,Noël JC, Tubular carcinoma of the breast and associated intra-epithelial lesions: a comparative study with invasive low-grade ductal carcinomas. Virchows Archiv : an international journal of pathology. 2005 Oct; [PubMed PMID: 16091953]|
|||Papadatos G,Rangan AM,Psarianos T,Ung O,Taylor R,Boyages J, Probability of axillary node involvement in patients with tubular carcinoma of the breast. The British journal of surgery. 2001 Jun; [PubMed PMID: 11412259]|
|||Elson BC,Helvie MA,Frank TS,Wilson TE,Adler DD, Tubular carcinoma of the breast: mode of presentation, mammographic appearance, and frequency of nodal metastases. AJR. American journal of roentgenology. 1993 Dec; [PubMed PMID: 8249721]|
|||Günhan-Bilgen I,Oktay A, Tubular carcinoma of the breast: mammographic, sonographic, clinical and pathologic findings. European journal of radiology. 2007 Jan; [PubMed PMID: 16987629]|
|||Winchester DJ,Sahin AA,Tucker SL,Singletary SE, Tubular carcinoma of the breast. Predicting axillary nodal metastases and recurrence. Annals of surgery. 1996 Mar; [PubMed PMID: 8604915]|
|||Mitnick JS,Gianutsos R,Pollack AH,Susman M,Baskin BL,Ko WD,Pressman PI,Feiner HD,Roses DF, Tubular carcinoma of the breast: sensitivity of diagnostic techniques and correlation with histopathology. AJR. American journal of roentgenology. 1999 Feb; [PubMed PMID: 9930775]|
|||Testempassi E,Sakuma T,Fukuda Y,Murakami Y,Harada J,Tada S,Suzuki M, Solid Tubular Carcinoma of the Breast: MR Imaging and Pathologic Correlation. Breast cancer (Tokyo, Japan). 1995 Apr 30; [PubMed PMID: 11091533]|
|||Cabral AH,Recine M,Paramo JC,McPhee MM,Poppiti R,Mesko TW, Tubular carcinoma of the breast: an institutional experience and review of the literature. The breast journal. 2003 Jul-Aug; [PubMed PMID: 12846864]|
|||Kitchen PR,Smith TH,Henderson MA,Goldhirsch A,Castiglione-Gertsch M,Coates AS,Gusterson B,Brown RW,Gelber RD,Collins JP, Tubular carcinoma of the breast: prognosis and response to adjuvant systemic therapy. ANZ journal of surgery. 2001 Jan; [PubMed PMID: 11167594]|
|||Livi L,Paiar F,Meldolesi E,Talamonti C,Simontacchi G,Detti B,Salerno S,Bianchi S,Cardona G,Biti GP, Tubular carcinoma of the breast: outcome and loco-regional recurrence in 307 patients. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2005 Feb; [PubMed PMID: 15642419]|
|||Jorns JM,Thomas DG,Healy PN,Daignault S,Vickery TL,Snider JE,Mardis ER,Davies SR,Ellis MJ,Visscher DW, Estrogen receptor expression is high but is of lower intensity in tubular carcinoma than in well-differentiated invasive ductal carcinoma. Archives of pathology [PubMed PMID: 25357113]|
|||Javid SH,Smith BL,Mayer E,Bellon J,Murphy CD,Lipsitz S,Golshan M, Tubular carcinoma of the breast: results of a large contemporary series. American journal of surgery. 2009 May; [PubMed PMID: 18789411]|